NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 15.30 against a street estimate of 14.93 — a beat of 2.5%.
with an average price target of ₹5,386.76.
| Document | Date |
|---|---|
| Q1 FY27 earnings call TORRENT PHARMACEUTICALS LIMITED – Q1 FY2026-27 SUMMARY DOCUMENT SCOPE LIMITATION • This is a regulatory filing letter dated 4th August 2026 notifyin | 2026-08-04 |
| Annual report FY2026 TORRENT PHARMACEUTICALS LIMITED – FY 2025-26 SUMMARY HEADLINE NUMBERS • Market Capitalisation: ₹1,428 billion (as at 31st March 2026) • Base busines | 2026-06-01 |
| Q4 FY26 earnings call TORRENT PHARMACEUTICALS LIMITED – Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Consolidated Q4 revenue: INR 4,197 crores, up 42% YoY • Operating EBIT | 2026-05-27 |
| Quarterly results · Q4 FY26 TORRENT PHARMACEUTICALS LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Year ended March 31, 2026 (FY2026): - Revenue from operations: ₹10,712 crore | 2026-05-22 |
| Investor presentation · Q4 FY26 TORRENT PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Q4 FY2025-26 Total Revenue: Rs 2,215 crore (up 43% from Rs 1,545 crore in Q4 | 2026-05-22 |
| Q3 FY26 earnings call DOCUMENT SUMMARY FOR RETAIL INVESTOR HEADLINE NUMBERS • This document is a regulatory filing letter dated 20th February 2026, not a financial results | 2026-02-20 |
| Quarterly results · Q3 FY26 TORRENT PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY Q3 & 9M FY2025-26 (Period Ended December 31, 2025) --- HEADLINE NUMBERS • Q3 Revenue from Opera | 2026-02-13 |
| Investor presentation TORRENT PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY Q3 & 9-MONTH RESULTS (ENDED 31 DECEMBER 2025) --- HEADLINE NUMBERS • Q3 FY2025-26 Total Revenue | 2026-02-13 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹9 / share ex-date May 29, 2026 | 2026-05-29 |
| Dividend | ₹29 / share ex-date Feb 18, 2026 · record Feb 19, 2026 | 2026-02-18 |
| Announcement | Date |
|---|---|
| Allotment of shares to J.B. Chemicals shareholders under amalgamation scheme Torrent Pharmaceuticals has completed the allotment of approximately 4.19 crore (41.9 million) new equity shares to shareholders of J.B. Chemicals & Pharmaceuticals Limited as part of a merg | 2026-07-20 |
| Interim dividend of Rs. 29 per equity share declared Torrent Pharmaceuticals Limited announced an interim dividend of Rs. 29 per equity share, approved by the Board of Directors on February 13, 2026. What happened: The company's board decided | 2026-02-13 |
| Interim dividend of 29 per equity share declared Torrent Pharmaceuticals' Board of Directors declared an interim dividend of ₹29 per equity share on February 13, 2026. An interim dividend is a cash payment distributed to shareholders befor | 2026-02-13 |
| Acquisition of equity shares in J.B. Chemicals & Pharmaceuticals Limited Torrent Pharmaceuticals has announced the acquisition of equity shares in J.B. Chemicals & Pharmaceuticals Limited. This is a strategic move in the pharmaceutical sector where Torrent is exp | 2026-02-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Torrent Pharmaceuticals Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.